CCHT(SZ:000661) Zheng Quan Ri Bao Zhi Sheng·2025-10-28 10:39Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received approval for clinical trials of GenSci098 injection, a novel monoclonal antibody for treating hyperthyroidism and related conditions [1][2]. Group 1 - GenSci098 injection is a humanized anti-thyroid-stimulating hormone receptor (TSHR) monoclonal antibody developed by Jinsai Pharmaceutical, aimed at treating hyperthyroidism by blocking TSHR interactions [1]. - The clinical trial approval is expected to facilitate the development of GenSci098 for patients with diffuse toxic goiter, a common cause of hyperthyroidism [2]. - Successful progress in clinical trials could enhance the company's business structure, optimize product offerings, and strengthen its competitive edge in the strategic field [2].